Affinity DataIC50: 1nMAssay Description:Inhibition of human recombinant BACE2 catalytic domain using FRET substrate with BACE-cleavable sequenceMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Recombinant BACE-2 (extracellular domain, expressed in baculovirus and purified using standard methods) at 0.1 to 10 nM concentrations is incubated w...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid receptor subunit alpha-1(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Displacement of [3H]flumazenil from GABAA receptor subunit alpha-1 expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMpH: 4.5 T: 2°CAssay Description:Recombinant BACE-2 (extracellular domain, expressed in baculovirus and purified using standard methods) at 0.1 to 10 nM concentrations is incubated w...More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid receptor subunit alpha-1(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Displacement of [3H]flumazenil from GABAA receptor subunit alpha-1 expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMpH: 4.5 T: 2°CAssay Description:Recombinant BACE-2 (extracellular domain, expressed in baculovirus and purified using standard methods) at 0.1 to 10 nM concentrations is incubated w...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of human recombinant BACE2 catalytic domain using FRET substrateMore data for this Ligand-Target Pair
TargetGamma-aminobutyric acid receptor subunit alpha-2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Displacement of [3H]flumazenil from GABAA receptor subunit alpha-2 expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Chinese hamster ovary cells are transfected with the human gene for amyloid precursor protein. The cells are plated at a density of 8000 cells/well i...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:Determination of Enzymatic PI3K Alpha and PI3K Delta Isoform Inhibition1.1 Test of Lipid Kinase ActivityThe efficacy of the compounds of examples 1-1...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type APP751 (unknown origin) expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type APP751 (unknown origin) expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type APP751 (unknown origin) expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type human APP751 expressed in CHO cells assessed as reduction in amyloid beta42 levelMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type human APP751 expressed in CHO cells assessed as reduction in amyloid beta(1 to 40 residues) levelMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of human recombinant BACE2 catalytic domain using FRET substrateMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of human recombinant BACE2 catalytic domain using FRET substrateMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type human APP751 expressed in CHO cells incubated for 24 hrs by immunoassayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type human APP751 expressed in CHO cells incubated for 24 hrs by immunoassayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type human APP expressed in CHO cells assessed as reduction in amyloid beta 40 secretion incubated for 24 hrs by immunoassayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of wild type human APP expressed in CHO cells assessed as reduction in amyloid beta 42 secretion incubated for 24 hrs by immunoassayMore data for this Ligand-Target Pair
TargetBeta-secretase 1(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of BACE1 (unknown origin) expressed in CHO cells co-expressing human APP751 assessed as decrease in amyloid beta 40 levels after 24 hrs by...More data for this Ligand-Target Pair
TargetBeta-secretase 1(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of BACE1 (unknown origin) expressed in CHO cells co-expressing human APP751 assessed as decrease in amyloid beta 40 levels after 24 hrs by...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMAssay Description:Chinese hamster ovary cells are transfected with the human gene for amyloid precursor protein. The cells are plated at a density of 8000 cells/well i...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Chinese hamster ovary cells are transfected with the human gene for amyloid precursor protein. The cells are plated at a density of 8000 cells/well i...More data for this Ligand-Target Pair